Merck's Zontivity gets FDA approval to reduce heart attacks and stroke risk in patients
Merck has received approval from the US Food and Drug Administration (FDA) for Zontivity (vorapaxar) for people at high-risk of heart attack or stroke.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Cardiology | Food and Drug Administration (FDA) | Heart | Heart Attack | Merck | Pharmaceuticals | Stroke